ARC-7

Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer

Study Name:
ARC-7 – Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer

Targeted Disease(s):
Lung Cancer

Purpose of Study:

This is an open-label phase 2 study in participants with non-small cell lung cancer which will assess the safety, efficacy and tolerability of zimberelimab as monotherapy and in combination with other immunotherapeutics across multiple treatment arms. Approximately 150 participants will be randomized to 1 of 3 treatment arms: 1) zimberelimab, 2) zimberelimab + domvanalimab (anti-TIGIT antibody), 3) zimberelimab + domvanalimab + etrumadenant (dual adenosine receptor antagonist). Participants that progress on the zimberelimab monotherapy arm may cross-over to receive the third arm combination of zimberelimab + domvanalimab + etrumadenant. The primary objective of this clinical study is to evaluate the efficacy of each combination therapy by assessing: 1) objective response rate (ORR) of participants with measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) and 2) progression free survival (PFS).

Study Dates:
May 1, 2020 - August 1, 2022

Type of Study:
Pre-Market

Study Design:
Controlled Design

Study Location:
Nationwide

Funding Source:
Arcus Biosciences

ClinicalTrails.gov Identifier:
NCT04262856

Freedom From Smoking Clinic
, | Oct 25, 2021
Community Connections: Air Quality & Lung Disease
, | Jan 19, 2022